Post marketing surveillance of ciprofloxacin-tinidazole combination

The post marketing surveillance of ciprofloxacin and tinidazole combination was designed to monitor clinical experience and adverse reactions of this combination in actual clinical settings. Though adequate efficacy and safety information is available on ciprofloxacin and tinidazole as individual drugs, there is no study on post marketing surveillance or adverse drug reaction monitoring of ciprofloxacin and tinidazole combination, so we decided to conduct this study in India. This study was conducted on 729 patients, with the help of 152 practising doctors all over India. This was an open, non-comparative post marketing surveillance study to monitor the clinical experience with ciprofloxacin 500mg and tinidazole 600mg combinations in adult patients in actual clinical settings. From the results of the study, it was observed that this combination is used in a variety of indications like surgical, gynaecological, gastrointestinal, bone and respiratory tract infections. A good response was observed in surgical, gynaecological and gastrointestinal infections while a satisfactory response was observed in bone infection. No adverse drug reaction was observed in 55% of the cases. In conclusion, our study confirms the efficacy of ciprofloxacin and tinidazole combination in various surgical, gynaecological and gastrointestinal infections. It also showed good results in dental, ENT, and respiratory tract infections and chronic osteomyelitis. This combination has also been used in paediatric patients with good results and no arthropathies. This study also showed that this ciprofloxacin and tinidazole combination is well tolerated in the Indian population